Antibody Engineering for Nuclear Imaging and Radioimmunotherapy. Academic Article uri icon

Overview

abstract

  • Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this "Focus on Molecular Imaging" review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs.

publication date

  • July 21, 2022

Research

keywords

  • Immunoconjugates
  • Radioimmunotherapy

Identity

PubMed Central ID

  • PMC9454464

Scopus Document Identifier

  • 85139572530

Digital Object Identifier (DOI)

  • 10.2967/jnumed.122.263861

PubMed ID

  • 35863894

Additional Document Info

volume

  • 63

issue

  • 9